Investment
Features
FeesSafety
Academy
More
Pluang+

Compare TransMedics Group Inc (TMDX) vs Texas Instruments Incorporated (TXN) Price & Performance

TransMedics Group IncTrade
Texas Instruments IncorporatedTrade

Price performance (Past 24H)

Key statistics

TransMedics Group Inc vs Texas Instruments Incorporated — how do they compare? TransMedics Group Inc trades at $87.27 (market cap $3.10B), while Texas Instruments Incorporated trades at $279.43 (market cap $256.84B). The key difference: Texas Instruments Incorporated is far larger — about 82.9× TransMedics Group Inc's market cap, and Texas Instruments Incorporated pays a 2.02% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.

TMDXTXN
Market Cap
$3.10B$256.84B
Sector
TechnologyTechnology
52-Week High
$150.42$332.35
52-Week Low
$61.99$153.33
Enterprise Value
$3.49B$263.89B
Dividend Yield
2.02%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

TransMedics Group Inc

TransMedics Group (TMDX) trades at $86.43, down 2.24% amid recent earnings misses but maintains strong analyst support with a $99.57 consensus target. The stock shows bullish technical signals with support at $84-87, though RSI levels suggest overbought conditions. Fundamentally, the company demonstrates robust profitability with 58.69% gross margins and 22.69% net income margins, despite recent quarterly earnings falling short of expectations.

Investment outlook remains positive given strong institutional backing and growth potential in organ transplant technology, though risks include ongoing fiduciary investigations and margin pressure from increased operating costs. The stock offers 15% upside to consensus targets but requires monitoring of Q3 earnings performance and legal developments.

Texas Instruments Incorporated

Texas Instruments (TXN) trades at $280.44, down 1.97% on the day, with a bullish technical signal from moving averages. Recent earnings show beats in Q1 and Q2 2026, with Q3 expected at $2.37 EPS. The company maintains strong profitability with a 31.11% net margin and a 34.97% ROE, though valuation ratios like a P/E of 42.74 appear elevated. Positive sentiment is driven by AI data center demand and a smooth CFO transition announced in June 2026.

Outlook is cautiously optimistic with a consensus price target of $334.75, implying 19% upside, supported by AI growth and operational leverage. Risks include high debt-to-asset ratio of 40.61% and competitive pressures in semiconductors. Investors should weigh strong cash flow and dividend yield against valuation concerns for long-term holdings.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About TransMedics Group Inc

TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.

Read more on TMDX

About Texas Instruments Incorporated

Dallas-based Texas Instruments generates over 95% of its revenue from semiconductors and the remainder from its well-known calculators. Texas Instruments is the world's largest maker of analog chips, which are used to process real-world signals such as sound and power. Texas Instruments also has a leading market share position in processors and microcontrollers used in a wide variety of electronics applications.

Read more on TXN